|
|
|
|
In this segment from the Bioprocess Online Live event, panelists discuss the most common challenges in scaling and transitioning a process into GMP manufacturing. They identify things such as supplier or CDMO constraints, facility fit, and technology transfers as some of the more prevalent challenges in this transition.
|
|
|
|
|
In this segment from the Bioprocess Online Live event, the panelists advise on what to do when no GMP-grade equivalents exist for certain starting materials. When an equivalent is unavailable, development teams must determine whether the material can still be used without compromising product quality.
|
|
|
|
|
In this segment from the Bioprocess Online Live event, panelists discuss how early-stage raw material decisions impact later-stage manufacturing and process performance, as well as the specific trade-offs to consider when it comes to raw materials for clinical manufacturing.
|
|
|
|
|
During this final segment from the Bioprocess Online Live event, a representative and SME enters the conversation. Mike Brewer, director and global principal consultant of regulatory and bioproduction, joins the panel for a Q&A session with the audience, discussing the challenges he’s witnessed companies face in the transition to clinical manufacturing.
|
|
|
|
|
